GLP-1 shortage status: what the FDA lists today

Short answer

Tirzepatide was listed in shortage until the FDA declared that shortage resolved on October 2, 2024, and confirmed that resolution in a declaratory order on December 19, 2024. Semaglutide’s shortage was declared resolved by the FDA on February 21, 2025. Neither medication is on the shortage list now.

Status checked November 13, 2026: neither semaglutide nor tirzepatide appears on the FDA drug shortage list.

Tirzepatide: resolved October 2, 2024

The FDA drug shortage database listed tirzepatide in shortage. The agency declared the shortage resolved on October 2, 2024, and then confirmed that resolution in a declaratory order on December 19, 2024. Those are two separate entries in the record: the resolution itself, and the order that confirmed it.

Semaglutide: resolved February 21, 2025

Semaglutide’s shortage was declared resolved by the FDA on February 21, 2025. From that day the shortage list no longer carried it, which left both medications off the list.

The two molecules did not leave the list on the same day. A shortage entry is a statement about supply; it is not a statement about a product’s approval, and it is not a price.

What a shortage listing allowed

While a drug was on the shortage list, that listing is what allowed pharmacy compounding of copies of it. In plain terms: the listed shortage was the circumstance that permitted a compounding pharmacy to prepare its own version of the medicine named on the list.

That is what the listing did. It did not approve the compounded copy as a product, and it did not make the copy interchangeable with the manufactured medicine. It described a supply gap, and it permitted something because of the gap.

What resolution changed

When the FDA declares a shortage resolved, the supply gap the listing described is recorded as closed. The permission that rested on the gap no longer rests on anything, so a compounding pharmacy can no longer point to the shortage as the reason it may make a copy of that medicine.

What did not change: the list entry disappearing does not approve a compounded product, does not restate any program’s terms, and does not alter what a program charges. This page describes what the listings said and what resolution means in ordinary language. It is not legal advice, and it is not a statement about how any particular pharmacy or program has behaved.

Compounded copies are not FDA-approved

Compounded semaglutide and compounded tirzepatide are not FDA-approved. A shortage listing never changed that, and a resolution does not change it either. The shortage list and the approval record are separate questions, and clearing the first has no bearing on the second.

Why this guide tracks cash prices

Because the shortage period is what made compounded versions of these two medicines familiar, this guide keeps a record of what programs charge in cash for them, and dates each figure it records. A status change on the shortage list is noted as a status change; it is never used here as evidence about a product, a price or an outcome. To see the programs themselves, start with the buyer guide; to see how each charge is read, dated and compared, read how we compare.